Global Radiopharmaceutical Theranostics 麻豆原创 Research Report 2023

Publication ID:

PB510231026

Publication Date:

October 23, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Retailing [2]

Consumer & Retail [3]

Description:

Nuclear medicine therapy uses radiopharmaceuticals targeting specific tumors, such as thyroid tumors, lymphomas, or bone metastases, to deliver radiation to neoplastic lesions as part of a therapeutic strategy to cure, alleviate, or control the disease.
The global Radiopharmaceutical Theranostics market is projected to reach US$ 986.5 million in 2029, increasing from US$ 745.6 million in 2022, with the CAGR of 4.1% during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Radiopharmaceutical Theranostics market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Nihon Medi-Physics
ITM Isotopen Technologien M眉nchen AG
Advanced Accelerator Applications
Telix Pharmaceuticals
GE Healthcare
Theragnostics Ltd.
NuView Life Sciences
Jubilant Pharma Limited
Lantheus Holdings, Inc.
Curium Pharma
Bayer AG
Clarity Pharmaceuticals
Segment by Type
Oncology
Cardiology
Others
Segment by Application
Hospitals
Academic & Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Radiopharmaceutical Theranostics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Radiopharmaceutical Theranostics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oncology
1.2.3 Cardiology
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Radiopharmaceutical Theranostics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Academic & Research Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radiopharmaceutical Theranostics 麻豆原创 Perspective (2018-2029)
2.2 Radiopharmaceutical Theranostics Growth Trends by Region
2.2.1 Global Radiopharmaceutical Theranostics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Radiopharmaceutical Theranostics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Radiopharmaceutical Theranostics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Radiopharmaceutical Theranostics 麻豆原创 Dynamics
2.3.1 Radiopharmaceutical Theranostics Industry Trends
2.3.2 Radiopharmaceutical Theranostics 麻豆原创 Drivers
2.3.3 Radiopharmaceutical Theranostics 麻豆原创 Challenges
2.3.4 Radiopharmaceutical Theranostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radiopharmaceutical Theranostics Players by Revenue
3.1.1 Global Top Radiopharmaceutical Theranostics Players by Revenue (2018-2023)
3.1.2 Global Radiopharmaceutical Theranostics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Radiopharmaceutical Theranostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radiopharmaceutical Theranostics Revenue
3.4 Global Radiopharmaceutical Theranostics 麻豆原创 Concentration Ratio
3.4.1 Global Radiopharmaceutical Theranostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radiopharmaceutical Theranostics Revenue in 2022
3.5 Radiopharmaceutical Theranostics Key Players Head office and Area Served
3.6 Key Players Radiopharmaceutical Theranostics Product Solution and Service
3.7 Date of Enter into Radiopharmaceutical Theranostics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Radiopharmaceutical Theranostics Breakdown Data by Type
4.1 Global Radiopharmaceutical Theranostics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Radiopharmaceutical Theranostics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Radiopharmaceutical Theranostics Breakdown Data by Application
5.1 Global Radiopharmaceutical Theranostics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Radiopharmaceutical Theranostics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Radiopharmaceutical Theranostics 麻豆原创 Size (2018-2029)
6.2 North America Radiopharmaceutical Theranostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Radiopharmaceutical Theranostics 麻豆原创 Size by Country (2018-2023)
6.4 North America Radiopharmaceutical Theranostics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radiopharmaceutical Theranostics 麻豆原创 Size (2018-2029)
7.2 Europe Radiopharmaceutical Theranostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Radiopharmaceutical Theranostics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Radiopharmaceutical Theranostics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radiopharmaceutical Theranostics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Radiopharmaceutical Theranostics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Radiopharmaceutical Theranostics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Radiopharmaceutical Theranostics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radiopharmaceutical Theranostics 麻豆原创 Size (2018-2029)
9.2 Latin America Radiopharmaceutical Theranostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Radiopharmaceutical Theranostics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Radiopharmaceutical Theranostics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radiopharmaceutical Theranostics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Radiopharmaceutical Theranostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Radiopharmaceutical Theranostics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Radiopharmaceutical Theranostics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Nihon Medi-Physics
11.1.1 Nihon Medi-Physics Company Detail
11.1.2 Nihon Medi-Physics Business Overview
11.1.3 Nihon Medi-Physics Radiopharmaceutical Theranostics Introduction
11.1.4 Nihon Medi-Physics Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.1.5 Nihon Medi-Physics Recent Development
11.2 ITM Isotopen Technologien M眉nchen AG
11.2.1 ITM Isotopen Technologien M眉nchen AG Company Detail
11.2.2 ITM Isotopen Technologien M眉nchen AG Business Overview
11.2.3 ITM Isotopen Technologien M眉nchen AG Radiopharmaceutical Theranostics Introduction
11.2.4 ITM Isotopen Technologien M眉nchen AG Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.2.5 ITM Isotopen Technologien M眉nchen AG Recent Development
11.3 Advanced Accelerator Applications
11.3.1 Advanced Accelerator Applications Company Detail
11.3.2 Advanced Accelerator Applications Business Overview
11.3.3 Advanced Accelerator Applications Radiopharmaceutical Theranostics Introduction
11.3.4 Advanced Accelerator Applications Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.3.5 Advanced Accelerator Applications Recent Development
11.4 Telix Pharmaceuticals
11.4.1 Telix Pharmaceuticals Company Detail
11.4.2 Telix Pharmaceuticals Business Overview
11.4.3 Telix Pharmaceuticals Radiopharmaceutical Theranostics Introduction
11.4.4 Telix Pharmaceuticals Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.4.5 Telix Pharmaceuticals Recent Development
11.5 GE Healthcare
11.5.1 GE Healthcare Company Detail
11.5.2 GE Healthcare Business Overview
11.5.3 GE Healthcare Radiopharmaceutical Theranostics Introduction
11.5.4 GE Healthcare Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.5.5 GE Healthcare Recent Development
11.6 Theragnostics Ltd.
11.6.1 Theragnostics Ltd. Company Detail
11.6.2 Theragnostics Ltd. Business Overview
11.6.3 Theragnostics Ltd. Radiopharmaceutical Theranostics Introduction
11.6.4 Theragnostics Ltd. Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.6.5 Theragnostics Ltd. Recent Development
11.7 NuView Life Sciences
11.7.1 NuView Life Sciences Company Detail
11.7.2 NuView Life Sciences Business Overview
11.7.3 NuView Life Sciences Radiopharmaceutical Theranostics Introduction
11.7.4 NuView Life Sciences Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.7.5 NuView Life Sciences Recent Development
11.8 Jubilant Pharma Limited
11.8.1 Jubilant Pharma Limited Company Detail
11.8.2 Jubilant Pharma Limited Business Overview
11.8.3 Jubilant Pharma Limited Radiopharmaceutical Theranostics Introduction
11.8.4 Jubilant Pharma Limited Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.8.5 Jubilant Pharma Limited Recent Development
11.9 Lantheus Holdings, Inc.
11.9.1 Lantheus Holdings, Inc. Company Detail
11.9.2 Lantheus Holdings, Inc. Business Overview
11.9.3 Lantheus Holdings, Inc. Radiopharmaceutical Theranostics Introduction
11.9.4 Lantheus Holdings, Inc. Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.9.5 Lantheus Holdings, Inc. Recent Development
11.10 Curium Pharma
11.10.1 Curium Pharma Company Detail
11.10.2 Curium Pharma Business Overview
11.10.3 Curium Pharma Radiopharmaceutical Theranostics Introduction
11.10.4 Curium Pharma Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.10.5 Curium Pharma Recent Development
11.11 Bayer AG
11.11.1 Bayer AG Company Detail
11.11.2 Bayer AG Business Overview
11.11.3 Bayer AG Radiopharmaceutical Theranostics Introduction
11.11.4 Bayer AG Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.11.5 Bayer AG Recent Development
11.12 Clarity Pharmaceuticals
11.12.1 Clarity Pharmaceuticals Company Detail
11.12.2 Clarity Pharmaceuticals Business Overview
11.12.3 Clarity Pharmaceuticals Radiopharmaceutical Theranostics Introduction
11.12.4 Clarity Pharmaceuticals Revenue in Radiopharmaceutical Theranostics Business (2018-2023)
11.12.5 Clarity Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Nihon Medi-Physics
ITM Isotopen Technologien M眉nchen AG
Advanced Accelerator Applications
Telix Pharmaceuticals
GE Healthcare
Theragnostics Ltd.
NuView Life Sciences
Jubilant Pharma Limited
Lantheus Holdings, Inc.
Curium Pharma
Bayer AG
Clarity Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.